UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2024

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

0-26642
(Commission File Number)

87-0494517
(IRS Employer Identification No.)

322 North 2200 West
Salt Lake City, Utah 84116
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600
Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.01 par value</td>
<td>MYGN</td>
<td>Nasdaq Global Select Market</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.07 Submissions of Matters to a Vote of Security Holders

On June 6, 2024, Myriad Genetics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 90,478,255 shares of Company common stock outstanding as of the record date of April 11, 2024, a quorum of 84,424,257 shares, or approximately 93% of the outstanding shares of Company common stock, was present via webcast or represented by proxy.

The following is a brief description of each matter submitted to a vote at the Annual Meeting, as well as the number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter.

Proposal No. 1: Election of Directors

<table>
<thead>
<tr>
<th></th>
<th>Votes For</th>
<th>Votes Against</th>
<th>Votes Abstained</th>
<th>Broker Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Louise Phanstiel</td>
<td>72,176,819</td>
<td>6,303,679</td>
<td>44,684</td>
<td>5,899,075</td>
</tr>
<tr>
<td>Daniel M. Skovronsky</td>
<td>77,928,386</td>
<td>557,211</td>
<td>39,585</td>
<td>5,899,075</td>
</tr>
</tbody>
</table>

Each of S. Louise Phanstiel and Daniel M. Skovronsky was elected to serve as a director of the Company for a term expiring at the 2027 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.

Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024

<table>
<thead>
<tr>
<th></th>
<th>Votes For</th>
<th>Votes Against</th>
<th>Votes Abstained</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>81,454,833</td>
<td>2,917,829</td>
<td>51,595</td>
</tr>
</tbody>
</table>

The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved by stockholders.

Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement

<table>
<thead>
<tr>
<th></th>
<th>Votes For</th>
<th>Votes Against</th>
<th>Votes Abstained</th>
<th>Broker Non-Votes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>74,410,679</td>
<td>4,060,490</td>
<td>54,013</td>
<td>5,899,075</td>
</tr>
</tbody>
</table>

The advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement, was approved by stockholders.
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: June 6, 2024

By:  /s/ Scott J. Leffler

Scott J. Leffler
Chief Financial Officer